Division of Molecular Genome Analysis

Prof. Dr. Stefan Wiemann

Regulation signaling network by miRNAs. Breast cancer cells were transfected with a library of 810 human miRNA mimics and induced effects were analyzed by quantitative analysis of 26 different proteins of the EGFR signaling network. Thus activating and inhibiting effects on protein abundance could be identified (left). High stringency miRNA-protein network with proteins being indicated in blue while miRNAs are in orange (right). Activating edges are in red, inhibiting edges in green.
© dkfz.de

Cancer and other human diseases arise from genetic aberrations that are either inherited or occur – as in most cancers – spontaneously in somatic cells. These defects cause abnormal activities of gene products that lead to malfunctioning of molecular and cellular interactions which, in consequence, may induce tumors and cause cancer progression.
The central objective of our division is to understand the complex molecular mechanisms that have evolved in the regulation of signaling networks and how these impact cancer development, metastasis, and drug resistance. To this end, we generate and maintain resources for large-scale experimentation, apply high-throughput functional genomics and proteomics technologies, and analyze candidate genes using in vitro as well as in vivo systems. Effects of perturbations (gene gain- and loss-of-function, miRNA, drugs) imposed on the signaling processes are experimentally tested and then computationally modeled. This generates mechanistic knowledge that is exploited to identify new diagnostic and prognostic markers, as well as to develop novel strategies for therapeutic intervention. Our major focus here is on breast cancer, where we investigate protein and non-protein factors that are involved in the progression of different subtypes via their activities in interrelated signaling networks.

FUTURE OUTLOOK
Our future research is mostly in two directions. We have already seen from our current data that signaling is not regulated in isolated pathways, but rather in complex networks. Therefore, in the future we will investigate the impact individual perturbations have on a variety of cellular pathways and at different levels (DNA, RNA, protein, metabolite, phenotype…). This should provide us with a better understanding of the connectivity between multi-layer interaction systems. Such information will be essential, for example, in identifying strategies that should help to overcome drug resistance. While much of our current knowledge is based on in vitro experiments, we need to validate findings in vivo in order to prove their relevance. To this end, we will generate and test animal models and challenge our hypotheses with patient samples. Projects to this end have been initiated and first promising results have already been obtained. Our research is funded mostly by national (BMBF, Landesstiftung Baden-Württemberg) and international (EU) agencies.

Contact

Prof. Dr. Stefan Wiemann
Molecular Genome Analysis (B050)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 580
69120 Heidelberg
Tel: +49 6221 42 4646
Fax: +49 6221 42 3454

Selected Publications

  • Wiemann S. et al. (2016). The ORFeome Collaboration: a genome-scale human ORF-clone resource. Nat Methods, 13(3), 191-192.
  • Haller F. et al. (2016). Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. J Pathol, 238(5), 700-710.
  • Keklikoglou I. et al. (2015). MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene, 34(37), 4867-4878.
  • Ben-Chetrit N. et al. (2015). Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Sci Signal, 8(360) ra7, 1-13.
to top